NCT07230834

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

A Phase 1 Dose-Escalation and Repeated-Dose Study of the Safety and Tolerability of Intravitreal Pozelimab in Participants With Geographic Atrophy

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 54 (estimated)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to see. This is called geographic atrophy (GA). The aim of the study is to see how safe and tolerable the study drug is when used as an injection in the eye. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

• Geographic Atrophy (GA)

Interventions

Type	Name	Description
DRUG	Pozelimab	Administered per the protocol

Timeline

• Start date: 2026-01-19
• Primary completion: 2028-07-03
• Completion: 2028-07-03
• First posted: 2025-11-17
• Last updated: 2026-03-05

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study